097 Novel Genomic Signature Predicts Response to Ruxolitinib Cream in Psoriasis
نویسندگان
چکیده
منابع مشابه
Genomic and molecular profiling predicts response to temozolomide in melanoma.
PURPOSE Despite objective response rates of only approximately 13%, temozolomide remains one of the most effective single chemotherapy agents against metastatic melanoma, second only to dacarbazine, the current standard of care for systemic treatment of melanoma. The goal of this study was to identify molecular and/or genetic markers that correlate with, and could be used to predict, response t...
متن کاملA novel microRNA signature predicts survival in stomach adenocarcinoma
Recent microRNA (miRNA) expression profiling studies suggest the clinical use of miRNAs as potential prognostic biomarkers in various malignancies. In this study, aiming to identify microRNAs with prognostic value for overall survival (OS) in stomach adenocarcinoma (STAD) patients, we analyzed the miRNA expression profiles and the associated clinical characteristics in 380 STAD samples from The...
متن کاملPersonalized medicine in psoriasis: developing a genomic classifier to predict histological response to Alefacept
BACKGROUND Alefacept treatment is highly effective in a select group patients with moderate-to-severe psoriasis, and is an ideal candidate to develop systems to predict who will respond to therapy. A clinical trial of 22 patients with moderate to severe psoriasis treated with alefacept was conducted in 2002-2003, as a mechanism of action study. Patients were classified as responders or non-resp...
متن کاملA Novel Patch-Based Digital Signature
In this paper a new patch-based digital signature (DS) is proposed. The proposed approach similar to steganography methods hides the secure message in a host image. However, it uses a patch-based key to encode/decode the data like cryptography approaches. Both the host image and key patches are randomly initialized. The proposed approach consists of encoding and decoding algorithms. The encodin...
متن کاملUnique Tracheal Fluid MicroRNA Signature Predicts Response to FETO in Patients With Congenital Diaphragmatic Hernia.
OBJECTIVE AND BACKGROUND Our objective was to determine the fetal in vivo microRNA signature in hypoplastic lungs of human fetuses with severe isolated congenital diaphragmatic hernia (CDH) and changes in tracheal and amniotic fluid of fetuses undergoing fetoscopic endoluminal tracheal occlusion (FETO) to reverse severe lung hypoplasia due to CDH. METHODS We profiled microRNA expression in pr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Investigative Dermatology
سال: 2019
ISSN: 0022-202X
DOI: 10.1016/j.jid.2019.07.101